Latest period
$9.48B
YoY change
-7.7%
5Y CAGR
-4.8%
Peak year (2021)
$29.87B
Latest annual
$9.08B
Free Cash Flow history chart for Pfizer (PFE) from 1989 to 2025
Latest: $9.08B
Free Cash Flow growth chart for Pfizer (PFE) from 1989 to 2025
Latest: -7.7%
Free Cash Flow history table for Pfizer (PFE) from 1989 to 2025
| 2025 | $9.08B | -7.7% | −$759.00M | ||
| 2024 | $9.84B | +105.2% | +$5.04B | ||
| 2023 | $4.79B | -81.6% | −$21.24B | ||
| 2022 | $26.03B | -12.8% | −$3.84B | ||
| 2021 | $29.87B | +157.2% | +$18.26B | ||
| 2020 | $11.61B | +16.2% | +$1.62B | ||
| 2019 | $9.99B | -26.7% | −$3.64B | ||
| 2018 | $13.63B | -4.4% | −$622.00M | ||
| 2017 | $14.25B | +2.5% | +$351.00M | ||
| 2016 | $13.90B | +6.8% | +$886.00M | ||
| 2015 | $13.02B | -14.9% | −$2.28B | ||
| 2014 | $15.30B | -6.1% | −$1.00B | ||
| 2013 | $16.30B | +3.6% | +$573.00M | ||
| 2012 | $15.73B | -15.4% | −$2.85B | ||
| 2011 | $18.58B | +86.9% | +$8.64B | ||
| 2010 | $9.94B | -35.4% | −$5.44B | ||
| 2009 | $15.38B | -7.0% | −$1.16B | ||
| 2008 | $16.54B | +44.1% | +$5.06B | ||
| 2007 | $11.47B | -26.2% | −$4.07B | ||
| 2006 | $15.54B | +23.1% | +$2.92B | ||
| 2005 | $12.63B | -8.1% | −$1.11B | ||
| 2004 | $13.74B | +51.0% | +$4.64B | ||
| 2003 | $9.10B | +8.0% | +$673.00M | ||
| 2002 | $8.43B | +19.3% | +$1.36B | ||
| 2001 | $7.06B | +76.3% | +$3.06B | ||
| 2000 | $4.00B | +167.8% | +$2.51B | ||
| 1999 | $1.50B | -13.6% | −$236.00M | ||
| 1998 | $1.73B | +152.3% | +$1.04B | ||
| 1997 | $686.00M | -46.9% | −$607.00M | ||
| 1996 | $1.29B | +14.9% | +$167.90M | ||
| 1995 | $1.13B | +37.7% | +$308.10M | ||
| 1994 | $817.00M | +29.9% | +$188.20M | ||
| 1993 | $628.80M | +373.5% | +$496.00M | ||
| 1992 | $132.80M | -47.7% | −$121.00M | ||
| 1991 | $253.80M | -18.9% | −$59.20M | ||
| 1990 | $313.00M | +57.0% | +$113.70M | ||
| 1989 | $199.30M | — | — |
- 2025$9.08B-7.7%
- 2024$9.84B+105.2%
- 2023$4.79B-81.6%
- 2022$26.03B-12.8%
- 2021$29.87B+157.2%
- 2020$11.61B+16.2%
- 2019$9.99B-26.7%
- 2018$13.63B-4.4%
- 2017$14.25B+2.5%
- 2016$13.90B+6.8%
- 2015$13.02B-14.9%
- 2014$15.30B-6.1%
- 2013$16.30B+3.6%
- 2012$15.73B-15.4%
- 2011$18.58B+86.9%
- 2010$9.94B-35.4%
- 2009$15.38B-7.0%
- 2008$16.54B+44.1%
- 2007$11.47B-26.2%
- 2006$15.54B+23.1%
- 2005$12.63B-8.1%
- 2004$13.74B+51.0%
- 2003$9.10B+8.0%
- 2002$8.43B+19.3%
- 2001$7.06B+76.3%
- 2000$4.00B+167.8%
- 1999$1.50B-13.6%
- 1998$1.73B+152.3%
- 1997$686.00M-46.9%
- 1996$1.29B+14.9%
- 1995$1.13B+37.7%
- 1994$817.00M+29.9%
- 1993$628.80M+373.5%
- 1992$132.80M-47.7%
- 1991$253.80M-18.9%
- 1990$313.00M+57.0%
- 1989$199.30M—
Free Cash Flow values are taken from Pfizer's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at Pfizer (PFE)
Free Cash Flow for Pfizer (PFE): headline value $9.48B · YoY -7.7%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Pfizer (PFE) most recent annual free cash flow stands at $9.08B (2025) – declined 7.7% year-over-year.
Through 2020–2025 (5 years), Pfizer free cash flow delivered a -4.8% annualised rate; with a net decline across the window.
Pfizer free cash flow peaked at $29.87B in 2021; the latest annual figure is $9.08B in 2025 (69.6% below peak).
The record annual free cash flow stands at $29.87B, reached in 2021; the historical low of $132.80M was recorded in 1992.
Pfizer Free Cash Flow by Year
Pfizer Free Cash Flow 2025: $9.08B
Pfizer free cash flow in 2025 was $9.08B, declined 7.7% below 2024.
Pfizer Free Cash Flow 2024: $9.84B
2024's free cash flow for Pfizer came in at $9.84B, surged 105.2% from 2023.
Pfizer Free Cash Flow 2023: $4.79B
Pfizer posted free cash flow of $4.79B in 2023, plunged 81.6% below 2022.
Pfizer Free Cash Flow 2022: $26.03B
In 2022, Pfizer reported free cash flow of $26.03B, declined 12.8% below 2021.
Pfizer Free Cash Flow 2021: $29.87B
Pfizer free cash flow in 2021 was $29.87B.
See more financial history for Pfizer (PFE).
Sector peers by Free Cash Flow
Healthcare peers of Pfizer (PFE), ranked by their latest free cash flow
| $19.70B | |
| $17.82B | |
| $16.07B | |
| $12.36B | |
| $8.97B | |
| $8.67B | |
| $8.10B | |
| $4.52B |
- $19.70B
- $17.82B
- $16.07B
- $12.36B
- $8.97B
- $8.67B
- $8.10B
- $4.52B
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation